Neurophth Therapeutics raises nearly **$95 million in Series C+ funding** to advance its **gene therapy clinical trials** for ophthalmic diseases. The company, based in China, focuses on developing treatments for eye conditions. Proceeds will support ongoing research and development in gene-based therapies targeting vision-related disorders.
Neurophth Therapeutics has enrolled the final patient in its Phase III clinical trial for a gene therapy treatment targeting Leber hereditary optic neuropathy (LHON) in China. The trial marks a key step toward potential commercialization of the therapy. Neurophth develops ocular gene therapies for inherited retinal diseases.
Neurophth Therapeutics secures over $60 million in Series C funding to develop gene therapies for neurological conditions. The company focuses on genomic medicines to address unmet medical needs. Neurophth integrates research, development, and manufacturing to accelerate treatment options.
Neurophth Biotechnology raises RMB 400 million in Series B funding to advance AAV-delivered gene therapies targeting ocular diseases. The company focuses on fully integrated genetic medicine solutions for eye conditions. This funding supports further development of its gene therapy pipeline.
